Nasrallah Henry A, Tandon Rajiv
Department of Psychiatry, University of Mississippi Medical Center, Jackson, Miss, USA.
J Clin Psychiatry. 2002;63 Suppl 13:12-20.
Schizophrenia is a serious and disabling psychiatric disorder affecting approximately 1% of the world's population, with its economic cost in the United States alone estimated to exceed that of all cancers combined. The new generation of atypical antipsychotics introduced over the past decade have comparable or greater efficacy than traditional antipsychotics in treating the psychotic symptoms of schizophrenia and a much improved neurologic side effect profile. Quetiapine, the fourth atypical antipsychotic marketed in the United States, was approved by the U.S. Food and Drug Administration in September 1997 and is also currently approved in over 70 countries worldwide for the treatment of psychosis associated with schizophrenia. This article will review the clinical trials examining the efficacy, safety, and tolerability of quetiapine in the treatment of patients with schizophrenia.
精神分裂症是一种严重且致残的精神障碍，影响着全球约1%的人口，仅在美国，其经济成本估计就超过了所有癌症的总和。过去十年推出的新一代非典型抗精神病药物在治疗精神分裂症的精神病症状方面，与传统抗精神病药物具有相当或更高的疗效，且神经副作用明显改善。喹硫平是在美国上市的第四种非典型抗精神病药物，于1997年9月获得美国食品药品监督管理局批准，目前在全球70多个国家也被批准用于治疗与精神分裂症相关的精神病。本文将综述关于喹硫平治疗精神分裂症患者的疗效、安全性和耐受性的临床试验。
